185 related articles for article (PubMed ID: 29406710)
1. Heterocyclic-Fused Pyrimidines as Novel Tubulin Polymerization Inhibitors Targeting the Colchicine Binding Site: Structural Basis and Antitumor Efficacy.
Banerjee S; Arnst KE; Wang Y; Kumar G; Deng S; Yang L; Li GB; Yang J; White SW; Li W; Miller DD
J Med Chem; 2018 Feb; 61(4):1704-1718. PubMed ID: 29406710
[TBL] [Abstract][Full Text] [Related]
2. Colchicine Binding Site Agent DJ95 Overcomes Drug Resistance and Exhibits Antitumor Efficacy.
Arnst KE; Wang Y; Lei ZN; Hwang DJ; Kumar G; Ma D; Parke DN; Chen Q; Yang J; White SW; Seagroves TN; Chen ZS; Miller DD; Li W
Mol Pharmacol; 2019 Jul; 96(1):73-89. PubMed ID: 31043459
[TBL] [Abstract][Full Text] [Related]
3. Design, synthesis and biological evaluation of a novel tubulin inhibitor 7a3 targeting the colchicine binding site.
Lai Q; Wang Y; Wang R; Lai W; Tang L; Tao Y; Liu Y; Zhang R; Huang L; Xiang H; Zeng S; Gou L; Chen H; Yao Y; Yang J
Eur J Med Chem; 2018 Aug; 156():162-179. PubMed ID: 30006162
[TBL] [Abstract][Full Text] [Related]
4. The compound millepachine and its derivatives inhibit tubulin polymerization by irreversibly binding to the colchicine-binding site in β-tubulin.
Yang J; Yan W; Yu Y; Wang Y; Yang T; Xue L; Yuan X; Long C; Liu Z; Chen X; Hu M; Zheng L; Qiu Q; Pei H; Li D; Wang F; Bai P; Wen J; Ye H; Chen L
J Biol Chem; 2018 Jun; 293(24):9461-9472. PubMed ID: 29691282
[TBL] [Abstract][Full Text] [Related]
5. A Potent, Metabolically Stable Tubulin Inhibitor Targets the Colchicine Binding Site and Overcomes Taxane Resistance.
Arnst KE; Wang Y; Hwang DJ; Xue Y; Costello T; Hamilton D; Chen Q; Yang J; Park F; Dalton JT; Miller DD; Li W
Cancer Res; 2018 Jan; 78(1):265-277. PubMed ID: 29180476
[TBL] [Abstract][Full Text] [Related]
6. Design, Synthesis, and Biological Evaluation of Heterocyclic-Fused Pyrimidine Chemotypes Guided by X-ray Crystal Structure with Potential Antitumor and Anti-multidrug Resistance Efficacy Targeting the Colchicine Binding Site.
Tan L; Wu C; Zhang J; Yu Q; Wang X; Zhang L; Ge M; Wang Z; Ouyang L; Wang Y
J Med Chem; 2023 Mar; 66(5):3588-3620. PubMed ID: 36802449
[TBL] [Abstract][Full Text] [Related]
7. Structure-Guided Design, Synthesis, and Biological Evaluation of (2-(1
Wang Q; Arnst KE; Wang Y; Kumar G; Ma D; White SW; Miller DD; Li W; Li W
J Med Chem; 2019 Jul; 62(14):6734-6750. PubMed ID: 31251599
[TBL] [Abstract][Full Text] [Related]
8. Design, Synthesis, and Biological Evaluation of 1-Methyl-1,4-dihydroindeno[1,2-c]pyrazole Analogues as Potential Anticancer Agents Targeting Tubulin Colchicine Binding Site.
Liu YN; Wang JJ; Ji YT; Zhao GD; Tang LQ; Zhang CM; Guo XL; Liu ZP
J Med Chem; 2016 Jun; 59(11):5341-55. PubMed ID: 27172319
[TBL] [Abstract][Full Text] [Related]
9. Synthesis and biological evaluation of 2,4,5-substituted pyrimidines as a new class of tubulin polymerization inhibitors.
Xie F; Zhao H; Li D; Chen H; Quan H; Shi X; Lou L; Hu Y
J Med Chem; 2011 May; 54(9):3200-5. PubMed ID: 21480626
[TBL] [Abstract][Full Text] [Related]
10. The high-resolution X-ray structure of vinca-domain inhibitors of microtubules provides a rational approach for drug design.
Chengyong W; Jinghong X; Yanyan W; Qing-Jie X; Lingling M; Yuyan L; Hai C; Qian L; Quan Z; Bo S; Yuxi W
FEBS Lett; 2021 Jan; 595(2):195-205. PubMed ID: 33220079
[TBL] [Abstract][Full Text] [Related]
11. Structure of a benzylidene derivative of 9(10H)-anthracenone in complex with tubulin provides a rationale for drug design.
Cheng J; Wu Y; Wang Y; Wang C; Wang Y; Wu C; Zeng S; Yu Y; Chen Q
Biochem Biophys Res Commun; 2018 Jan; 495(1):185-188. PubMed ID: 29102632
[TBL] [Abstract][Full Text] [Related]
12. Design, Synthesis, and Biological Evaluation of Pyrimidine Dihydroquinoxalinone Derivatives as Tubulin Colchicine Site-Binding Agents That Displayed Potent Anticancer Activity Both In Vitro and In Vivo.
Pochampally S; Hartman KL; Wang R; Wang J; Yun MK; Parmar K; Park H; Meibohm B; White SW; Li W; Miller DD
ACS Pharmacol Transl Sci; 2023 Apr; 6(4):526-545. PubMed ID: 37082747
[TBL] [Abstract][Full Text] [Related]
13. Synthesis and biological evaluation of pyrimidine bridged combretastatin derivatives as potential anticancer agents and mechanistic studies.
Kumar B; Sharma P; Gupta VP; Khullar M; Singh S; Dogra N; Kumar V
Bioorg Chem; 2018 Aug; 78():130-140. PubMed ID: 29554587
[TBL] [Abstract][Full Text] [Related]
14. BZML, a novel colchicine binding site inhibitor, overcomes multidrug resistance in A549/Taxol cells by inhibiting P-gp function and inducing mitotic catastrophe.
Bai Z; Gao M; Zhang H; Guan Q; Xu J; Li Y; Qi H; Li Z; Zuo D; Zhang W; Wu Y
Cancer Lett; 2017 Aug; 402():81-92. PubMed ID: 28576750
[TBL] [Abstract][Full Text] [Related]
15. Design, synthesis, biological evaluation and cocrystal structures with tubulin of chiral β-lactam bridged combretastatin A-4 analogues as potent antitumor agents.
Zhou P; Liang Y; Zhang H; Jiang H; Feng K; Xu P; Wang J; Wang X; Ding K; Luo C; Liu M; Wang Y
Eur J Med Chem; 2018 Jan; 144():817-842. PubMed ID: 29306206
[TBL] [Abstract][Full Text] [Related]
16. Design, synthesis and biological evaluation of quinoline-indole derivatives as anti-tubulin agents targeting the colchicine binding site.
Li W; Shuai W; Sun H; Xu F; Bi Y; Xu J; Ma C; Yao H; Zhu Z; Xu S
Eur J Med Chem; 2019 Feb; 163():428-442. PubMed ID: 30530194
[TBL] [Abstract][Full Text] [Related]
17. Discovery of novel tubulin inhibitors via structure-based hierarchical virtual screening.
Cao R; Liu M; Yin M; Liu Q; Wang Y; Huang N
J Chem Inf Model; 2012 Oct; 52(10):2730-40. PubMed ID: 22992059
[TBL] [Abstract][Full Text] [Related]
18. Discovery of potent cytotoxic ortho-aryl chalcones as new scaffold targeting tubulin and mitosis with affinity-based fluorescence.
Zhu C; Zuo Y; Wang R; Liang B; Yue X; Wen G; Shang N; Huang L; Chen Y; Du J; Bu X
J Med Chem; 2014 Aug; 57(15):6364-82. PubMed ID: 25061803
[TBL] [Abstract][Full Text] [Related]
19. Semisynthetic aurones inhibit tubulin polymerization at the colchicine-binding site and repress PC-3 tumor xenografts in nude mice and myc-induced T-ALL in zebrafish.
Xie Y; Kril LM; Yu T; Zhang W; Frasinyuk MS; Bondarenko SP; Kondratyuk KM; Hausman E; Martin ZM; Wyrebek PP; Liu X; Deaciuc A; Dwoskin LP; Chen J; Zhu H; Zhan CG; Sviripa VM; Blackburn J; Watt DS; Liu C
Sci Rep; 2019 Apr; 9(1):6439. PubMed ID: 31015569
[TBL] [Abstract][Full Text] [Related]
20. Structural Modification of the 3,4,5-Trimethoxyphenyl Moiety in the Tubulin Inhibitor VERU-111 Leads to Improved Antiproliferative Activities.
Wang Q; Arnst KE; Wang Y; Kumar G; Ma D; Chen H; Wu Z; Yang J; White SW; Miller DD; Li W
J Med Chem; 2018 Sep; 61(17):7877-7891. PubMed ID: 30122035
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
